TMSP(SH:600671)2024-06-04 14:12Financial Performance - The company's operating revenue for Q1 2024 was ¥27,735,233.63, representing a year-on-year increase of 24.64%[4]. - Total revenue for Q1 2024 reached ¥27,735,233.63, an increase of 24% compared to ¥22,252,900.21 in Q1 2023[24]. - The net loss for Q1 2024 was ¥9,722,239.23, compared to a loss of ¥1,371.68 in Q1 2023, indicating a significant increase in losses[24]. - The net profit for Q1 2024 was -10,098,459.85 RMB, compared to -9,973,874.17 RMB in Q1 2023, indicating a decline in profitability[25]. - The total comprehensive loss for Q1 2024 was -10,098,459.85 RMB, compared to -9,973,874.17 RMB in Q1 2023[26]. - The company reported a basic and diluted earnings per share of -0.0798 RMB for Q1 2024, compared to -0.0744 RMB in Q1 2023[26]. - The total operating profit of -10,916,187.17 RMB for Q1 2024, compared to -8,301,111.27 RMB in Q1 2023[25]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥3,573,723.68, indicating a significant cash outflow[4]. - The cash flow from operating activities for Q1 2024 was -3,573,723.68 RMB, an improvement from -11,989,424.41 RMB in Q1 2023[30]. - The company's cash and cash equivalents decreased by 42.92% due to the repayment of bank loans amounting to ¥30 million[8]. - Cash and cash equivalents at the end of Q1 2024 were 55,920,693.46 RMB, a decrease from 26,809,514.56 RMB at the end of Q1 2023[31]. - The total cash outflow from financing activities in Q1 2024 was 157,310,537.66 RMB, compared to 87,447,078.37 RMB in Q1 2023[30]. Assets and Liabilities - The total assets at the end of the reporting period were ¥312,679,319.64, a decrease of 9.71% compared to the end of the previous year[5]. - Total assets decreased to ¥312,679,319.64 from ¥346,288,556.33, a decline of about 10%[22]. - Total liabilities decreased to ¥266,829,318.90 from ¥290,340,095.74, reflecting a reduction of approximately 8%[22]. - The equity attributable to shareholders decreased by 26.18% to ¥27,415,273.59 compared to the end of the previous year[5]. - The company reported a decrease in total equity to ¥45,850,000.74 from ¥55,948,460.59, a decline of about 18%[22]. Investments and Acquisitions - The company acquired 51% equity of Qingdao Yuanjia Shengding Holdings Co., Ltd. for a cash price of RMB 165,000, with a paid-in capital of RMB 2.1012 million[15]. - The net cash flow from investing activities showed a significant outflow increase of 166.82% due to payments made for acquiring subsidiaries[9]. Shareholder Information - The company reported a total of 36,519,460 shares held by Qingdao Huilong Huaze Investment Co., Ltd., representing 29.99% of total shares[12]. - The company has a total of 15,045,900 shares held by Qingdao Yuanjia Medical Technology Co., Ltd., accounting for 12.36% of total shares[12]. - The company has a total of 5,181,813 shares held by Zhejiang Qingfeng Original Culture Co., Ltd., representing 4.26% of total shares[12]. - The company has a total of 4,000,000 shares held by Hangzhou Yuedianrun Investment Management Partnership, accounting for 3.28% of total shares[12]. Legal and Regulatory Matters - The company reported a civil judgment requiring repayment of RMB 3,852,300.79, with interest calculated at an annual rate of 15.4%[16]. - The company has resolved its guarantee liability related to a loan interest payment of RMB 1,118,700[17]. - The company held its first temporary shareholders' meeting on April 15, 2024, to elect a new supervisor[14]. - The company has not reported any changes in the participation of major shareholders in financing or securities lending activities[13]. Research and Development - Research and development expenses were reported at ¥1,371.68 in Q1 2023, indicating a focus on innovation despite financial losses[24]. Financial Statements - The company’s financial statements for the first quarter of 2024 are unaudited[18].